Diagnosis & Differentiation
Trop-2 expression is associated with poor survival in pleural mesothelioma
Frontiers in Oncology 2026 May 29 [Link] Alejandro Aviles-Salas, Norma Hernández-Pedro, Enrique Caballé-Perez, José Lucio-Lozada, César Castillo-Ruiz, José Gregorio Chanona-Vilchis, Alejandro Aranda-Gutierrez, Mario Orozco-Morales, Pedro Barrios-Bernal, Rafael Parra-Medina, Luis Cabrera-Miranda, Andrés F Cardona, Oscar Arrieta Abstract Introduction: Pleural mesothelioma (PM) lacks reliable biomarkers to guide therapy. Trophoblast cell-surface antigen 2 (Trop-2) is targetable in epithelial…
Read MoreThe diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma – A systematic review and meta-analysis
Seminars in Nuclear Medicine 2026 June 10 [Link] Anne H Thostrup, Natasja U Stubbe, Mathias P Schreiner, Morten Bentestuen, Anne V Olesen, Helle D Zacho Abstract Purpose: This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of FDG PET/CT for diagnosing pleural mesothelioma in treatment-naïve patients using histopathology as reference standard. Secondary aims…
Read MoreThe Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves
Current Oncology Reports 2026 June 8 [Link] Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta Abstract Purpose of review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum-pemetrexed chemotherapy has persisted as the…
Read MoreA High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreIncreased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreThe role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy
Lung Cancer 2026 July [Link] Farhad Kosari, Paul Baas, Maria Disselhorst, Kim Lauer, Tobias Peikert, Stephen Murphy, Janet Schaefer Klein, Aaron S Mansfield Abstract Assessing the contributions of microRNAs to gene expression regulation and treatment outcomes in malignancies is challenging. Traditional analyses focus on individual microRNAs, overlooking competitive binding among RNA species sharing common microRNAs.…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreA case of diffuse malignant peritoneal mesothelioma: case report and literature review
Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…
Read MoreQuantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort
Academic Radiology 2026 May 15 [Link] Ritu R Gill, William G Richards, Emanuele Mazzola, Beow Y Yeap, Raphael Bueno Abstract Rationale and objectives: Accurate clinical staging in pleural mesothelioma (PM) is limited by the subjectivity of conventional imaging assessment, which introduces inter- and intraobserver variability. Tumor volume, pleural thickness and diaphragmatic thickness measurements individually prognostic…
Read More
Skip to content